^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFR inhibitor

    Related drugs:
    21h
    The function and mechanism of LINC01583 on Osimertinib resistance in non-small cell lung cancer. (PubMed, Mol Cell Probes)
    In this study, we revealed LINC01583 as a key oncogenic driver that promotes both NSCLC progression and Osi resistance by functioning as a ceRNA for miR-4640-5p, thereby upregulating its target gene CHD8.
    Journal
    |
    CHD8 (Chromodomain Helicase DNA Binding Protein 8)
    |
    Tagrisso (osimertinib)
    21h
    Testing brigatinib in an oncological patient's hair: Evaluation of the time of disappearance after discontinuation and interpretation of concentrations obtained in regrowing hair after total loss. (PubMed, Clin Chim Acta)
    Despite a quite stable drug dosage, brigatinib levels fluctuated, suggesting an influence of chemotherapy-induced hair alterations on drug incorporation. Moreover, brigatinib remained detectable in hair up to eight months after treatment discontinuation.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Alunbrig (brigatinib)
    1d
    Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. (PubMed, Lung Cancer)
    Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated EGFR-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Lazcluze (lazertinib)
    1d
    PALOMA-2: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=520, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Aug 2028
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    2d
    HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (clinicaltrials.gov)
    P2, N=40, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    2d
    ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Semena (befotertinib)
    2d
    OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov)
    P3, N=1000, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2032 --> Jan 2032
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium
    2d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Oct 2026
    Enrollment open • Trial initiation date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
    2d
    Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients. (PubMed, Adv Ther)
    Clinical outcomes for patients receiving 2L therapy post-osimertinib progression remain poor, highlighting an unmet need, particularly for those with brain and liver metastases.
    Clinical data • Journal • Real-world evidence • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    2d
    Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine. (PubMed, Tissue Cell)
    Berberine overcomes osimertinib resistance by targeting the Notch1 pathway and reversing EMT, providing a novel strategy to enhance EGFR-TKI efficacy in NSCLC and supporting integration of traditional Chinese medicine with targeted therapies.
    Journal
    |
    NOTCH1 (Notch 1)
    |
    Tagrisso (osimertinib)
    2d
    [Expression of Concern] Interference of STAT 5b expression enhances the chemo‑sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway‑mediated cell apoptosis. (PubMed, Oncol Rep)
    Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Molecular Medicine Reports 34: 227‑234, 2015; DOI: 10.3892/or.2015.3994].
    Journal
    |
    CASP3 (Caspase 3) • CASP9 (Caspase 9)
    |
    gefitinib